PRA Health Sciences Named Best CRO in Asia


RALEIGH, N.C., March 06, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is honored to once again be named Best CRO in Asia. PRA received this recognition at the Phar-East Pharma and Biotech Festival (formally known as BioPharma Asia). This is the fourth time PRA has received this award since 2013. The award recognizes the best CRO that has demonstrated an ongoing commitment to improve their clinical research services in Asia and in reducing lead times for its customers.

"This award is possible thanks to our exceptional Asia Pacific team," said David MacMurchy, Executive Vice President, Europe Asia Pacific and Africa. "PRA has continued to invest in the best talent and infrastructure globally and this includes Asia Pacific. I am extremely pleased that the team has been recognized and excited to continue building and investing to support clients and patients in the region."

PRA has been strategically expanding its Asia Pacific operations since 2000 and has supported 345 clinical trials in the region at 4300+ sites across Australia, China, Hong Kong, India, Japan, Malaysia, New Zealand, the Philippines, Singapore, South Korea, Taiwan, and Thailand.

PRA has established a sophisticated infrastructure of in-house clinical research professionals throughout Asia Pacific, with more than 1000 local clinical and project management staff delivering comprehensive services in 12 countries. Through our Strategic Solutions Division, PRA also provides Embedded Solutions(TM) in which our teams integrate into the client's internal clinical development operations, managing functions across the breadth of their development pipeline. Our Strategic Solutions offerings represent an innovative alternative to traditional development approaches allowing clients to maintain greater control over their clinical development processes while providing significant cost savings.


PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes More than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit

Media Inquiries: Christine Rogers, Director, Public Relations, Corporate Communications

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PRA Health Sciences via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00Pressmeddelande

End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to

McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions20.3.2018 09:03Pressmeddelande

Company Expected to Prevent 150 Million Metric Tons of Emissions by 2030 OAK BROOK, Ill., March 20, 2018 (GLOBE NEWSWIRE) -- Today, McDonald's announces it will partner with franchisees and suppliers to reduce greenhouse gas emissions related to McDonald's restaurants and offices by 36% by 2030 from a 2015 base year in a new strategy to address global climate change. Additionally, McDonald's commits to a 31% reduction in emissions intensity (per metric ton of food and packaging) across its supply chain by 2030 from 2015 levels. This combined target has been approved by the Science Based Targets initiative(SBTi). Through these actions, McDonald's expects to prevent 150 million metric tons of greenhouse gas emissions from being released into the atmosphere by 2030. This is the equivalent of taking 32 million passenger cars off the road for an entire year or planting 3.8 billion trees and growing them for 10 years. The target will enable McDonald's to grow as a business without growing it

Momentum Group acquires Reklamproffsen in Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) has acquired 70 percent of the shares in Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen is a leading reseller of promotional products, including workwear and profile clothing, in Örebro and the surrounding area. Reklamproffsen generates annual revenue of approximately MSEK 35 with favourable profitability and has 12 employees. Reklamproffsen is one of Örebro's largest resellers of workwear and profile clothing, with a high level of expertise in customising company products. Reklamproffsen has a professional store and showroom in Örebro. Its customers mainly comprise industrial and service companies, and a significant portion of its sales are conducted via customised online stores. "Thanks to its strong customer and supplier relationships and highly skilled employees, Reklamproffsen has achieved successful growth since it was formed in 2000. It is now a well-established company in Örebro and the surrounding area. We anticipate good opportuniti

Momentum Group förvärvar Reklamproffsen i Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) har förvärvat 70 procent av aktierna i Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen är en ledande återförsäljare av produktmedia innefattande yrkeskläder och profilkläder i Örebro med omnejd. Reklamproffsen omsätter cirka 35 MSEK per år med god lönsamhet och har 12 anställda. Reklamproffsen är en av Örebros största återförsäljare inom yrkeskläder och profilkläder med hög kompetens inom företagsprofilering. Reklamproffsen har en yrkesbutik och utställning i Örebro. Kunderna utgörs främst av industri- och serviceföretag och en betydande andel av försäljningen sker via kundunika webbshoppar. - Reklamproffsen har med sina starka kund- och leverantörsrelationer och medarbetare med hög kompetens utvecklats framgångsrikt ända sedan starten år 2000. Bolaget är idag ett väletablerat företag i Örebro med omnejd. Vi ser mycket goda möjligheter till vidare utveckling och tillväxt för Reklamproffsen som en del av Momentum Group, säger Ulf Lilius, VD & K

Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data20.3.2018 08:00Pressmeddelande

Press Release 20 March 2018 Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that its lead product candidate, ilixadencel, has been granted an Advanced Therapy Medicinal Product (ATMP) certificate following a review of manufacturing quality and non-clinical data by the European Medicines Agency (EMA). "The EMA ATMP certificate is an important development milestone for ilixadencel because it validates our manufacturing quality and preclinical data and gives us a firm foundation for the later stages of clinical development. Cell-based therapies must meet very high requirements and we are pleased to have this recognition from the EMA of our work to date," said Carlos de Sousa, CEO of Immunicum. "Immunicum is one of very few companies that have successfully u

Immunicum AB: Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data20.3.2018 08:00Pressmeddelande

Pressmeddelande 20 mars 2018 Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data Immunicum AB (publ; IMMU.ST) ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att bolagets ledande produktkandidat, ilixadencel, har erhållit en ATMP-certifiering (Advanced Therapy Medicinal Product) efter granskning av tillverkningskvalitet och prekliniska data av den europeiska läkemedelsmyndigheten EMA (European Medicines Agency). "EMAs ATMP certifikat är en viktig milstolpe i utvecklingen av ilixadencel eftersom det validerar vår tillverkningskvalitet och våra prekliniska data, och ger oss samtidigt en solid bas för de senare faserna i den kliniska utvecklingen. Cell-baserade terapier måste uppfylla mycket höga krav och vi är glada att få detta erkännande av EMA för vårt arbete så här långt," säger Carlos de Sousa, VD för Immunicum. "Immunicum ä

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum